These PDMP-combined treatments did not significantly affect bone marrow stem cells (ABCG2+), nor did they impact GCS activities of bone marrow, either in SW48- or TP53-tumor-bearing mice (Supplementary Figure S1A, S1B). The gene discussed is TP53; the disease is neoplasm.